Holen Sie sich die Stockscreener-App
0.2484
4.57%
-0.0119
Handel nachbörslich:
.40
0.1516
+61.03%
Silexion Therapeutics Corp Aktie (SLXN) Neueste Nachrichten
Form PRE 14A SILEXION THERAPEUTICS CORP For: 26 September By Investing.com - Investing.com India
Price to sales forward of Silexion Therapeutics Corp – NASDAQ:SLXN - TradingView
Silexion Therapeutics Notified of Nasdaq Bid Price Deficiency, Trading Continues Unaffected - Kalkine Media
Silexion Therapeutics Receives Nasdaq Bid Price Deficiency Notice - TipRanks
Silexion Therapeutics Corp (SLXNW) Stock Price, News, Quote & History - Yahoo Finance
Why Is the Market Watching Silexion Therapeutics (SLXN)? - kalkinemedia.com
Biotech Pre-Market Movers: TNON, AEON Surge; COO, CDT Slide - RTTNews
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences - GlobeNewswire
SLXN Q2 2026 Earnings: Loss Per Share of -$5.17 Misses Estimates by 139.09% as Company Remains Pre-RevenueNew Analyst Coverage - dars.gov.et
After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN) - TipRanks
Silexion (SLXNW) Range: Finishes Nearly Flat at $0.01 in Latest Trading; Next Test - dars.gov.et
Silexion Therapeutics Receives Nasdaq Delisting Notice, Plans Appeal - The Globe and Mail
Silexion Therapeutics Received Notice of Delisting - TradingView
Top Silexion Therapeutics CorpWarrant (SLXNW) Competitors 2026 - MarketBeat
Silexion Therapeutics Executes Reverse Share Split Amid Strain - The Globe and Mail
Silexion Therapeutics Closes Public Offering and Strengthens Equity - The Globe and Mail
Silexion Therapeutics (SLXN) seeks huge share boost and reverse split to stay on Nasdaq - Stock Titan
Silexion Q2 EPS $(5.17) misses $(2.12) estimate; loss widens - scanx.trade
Silexion Therapeutics Raises $35 Million in August Public Offering - Minichart
Silexion Therapeutics Corp 2Q 2026: Net loss $3.55M, EPS $(12.41) — 10-Q Summary - TradingView
Silexion Initiates Phase 2/3 Pancreatic Cancer Trial on July 29 - Minichart
Silexion Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Silexion Reports $3.6 Million Second-Quarter Net Loss as SIL204 Trial Starts - Moomoo
Silexion Therapeutics reports Q2 2026: $3.6M Q2 net loss, $2.2M cash at June 30 - TradingView
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Press Release: Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Silexion Completes 1-for-10 Reverse Share Split - Minichart
Form 8K Silexion Therapeutics Corp For: 13 August By Investing.com - Investing.com Nigeria
Silexion Therapeutics Corp (SLXN) investors report 0% holding but retain warrants - Stock Titan
Silexion Therapeutics Corp SEC Filing (Aug 12, 2026) - Stock Titan
Silexion Therapeutics Prices $2.5 Million Securities Offering; Shares Down Pre-Bell - marketscreener.com
Silexion Therapeutics prices $2.5M public offering at $0.65 By Investing.com - Investing.com India
Silexion prices $2.5M offering to fund KRAS cancer trial - Dealroom
Silexion Therapeutics prices $2.5M public offering at $0.65 - Investing.com
Silexion Intends to Use Offering Proceeds for Pancreatic Trial - Stock Titan
Silexion Therapeutics Prices $2.5 Million Public Offering of Ordinary Shares and Warrants - Quiver Quantitative
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering - GlobeNewswire
SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Falls 31%Earnings Revision Upgrade - dars.gov.et
SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, Yet Shares Tumble 29%GAAP Earnings Report - dars.gov.et
Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) - TipRanks
Immunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) - Benzinga
Immunotherapy's Biggest Blind Spot Is A $7 Billion Market. Silexion May Have A Way In (NASDAQ: SLXN) - Menafn
Form 8K Silexion Therapeutics Corp For: 10 August By Investing.com - Investing.com South Africa
Silexion Updates SIL204 Clinical and Regulatory Roadmap - tipranks.com
Silexion Therapeutics (SLXN US): Synthetic Expert Call Transcript (10 Aug 2026) - Smartkarma
Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers - Bitget
Maxim Group Maintains Silexion Therapeutics(SLXN.US) With Hold Rating - 富途牛牛
IPO Databook: Silexion Therapeutics (SLXN US)Aug 2026 - Smartkarma
Silexion Therapeutics (NASDAQ: SLXN) files S-1 for best-efforts unit sale - Stock Titan
Silexion Therapeutics Warrant (SLXNW) Holds Flat at $0.02 as Trading Range CompressesAdvance Decline Line - careplusvn.com
Silexion unveils key SIL204 KRAS preclinical findings - TipRanks
Silexion to present preclinical data on SIL-204 at GI cancer event - Investing.com
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers - The Manila Times
Silexion Therapeutics Reports Preclinical Data Showing SIL204 Immune-Sensitizing Effects in KRAS-Mutant Cancer Cells - Quiver Quantitative
Silexion's SIL204 Alters Three Immune Pathways in Cancer Cells - Stock Titan
Silexion Therapeutics Reports New Positive Preclinical - GlobeNewswire
Silexion Therapeutics Restores Nasdaq Audit Committee Compliance - TipRanks
0.14%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):